Long COVID Linked to Brain Dopamine Changes in New Study
- Long COVID is linked to physical changes in brain nerve endings tied to dopamine production, according to a preliminary study published in the journal eBioMedicine and reported by...
- Patients who experienced severe symptoms showed larger alterations in nerve endings connected to dopamine.
- Jeffrey Meyer, a psychiatrist at the Brain Health Imaging Centre in Canada, stated that the results provide strong evidence pointing toward a loss or decline in the function...
Long COVID is linked to physical changes in brain nerve endings tied to dopamine production, according to a preliminary study published in the journal eBioMedicine and reported by Science Alert. The Canadian research compared 24 individuals suffering from long COVID against healthy participants of the same age group.
Dopamine Pathway Changes and Patient Symptoms
Patients who experienced severe symptoms showed larger alterations in nerve endings connected to dopamine. Dopamine is a central chemical messenger responsible for regulating motivation, learning, and the brain reward system. Disruptions in this system frequently trigger memory issues, slow movement, and a loss of drive.
Jeffrey Meyer, a psychiatrist at the Brain Health Imaging Centre in Canada, stated that the results provide strong evidence pointing toward a loss or decline in the function of dopamine-producing nerve cells in certain long COVID patients. Previous research into the condition concentrated on brain inflammation and immune system shifts. This study directly investigates the impact on dopamine neurons.
Potential Mechanisms Driving Brain Cell Damage
Researchers outline two primary mechanisms that could explain the neural damage. Some long COVID patients display signs of active brain immune cells that damage or disrupt synapses. Additionally, the SARS-CoV-2 virus may directly target dopamine-secreting neurons because these cells possess specific receptors that allow the virus to bind or enter.
The imaging technique used in the study measured specific proteins located at the ends of dopaminergic nerves. While this method does not directly count neurons, it permits the observation of cellular changes in living patients. Definitive proof of neuron loss still requires post-mortem brain tissue analysis, though a prior small autopsy study observed a drop in these cells among patients who died from severe COVID-19. That earlier study faced limitations due to age and early signs of neurodegenerative conditions in some subjects.
Future Treatment Approaches for Long COVID
Targeting dopamine pathways could establish an entirely new treatment path, moving away from current methods that ignore these specific nerve cells. If larger studies confirm the findings, medical professionals could test existing Parkinson’s disease medications like levodopa to alleviate certain long COVID symptoms. Scientists caution against rushing to use these drugs because of potential side effects and the likelihood that benefits would only help specific patient subgroups.
Investigators stress that long COVID is not a uniform illness. Symptoms vary widely among individuals, indicating that dopamine system disruption accounts for only a portion of cases rather than the entire patient population.